Saturday 17 October 2026
Export PLRX’s income statement to Excel — free account
Pliant Therapeutics, Inc.
PLRX Healthcare Biotechnology
Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022. In the quarter to June 2026, EPS grew 49.3% and free cash flow grew 68.6%, each against the same quarter a year earlier.
0.90
0.07
−7.22%
Follow PLRX
Pliant Therapeutics, Inc. (PLRX) P/E ratio
Pliant Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 11.8× (March 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 6.7× | 380.59% |
| FY2019 | 1.4× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 11.8×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | n/m |
| BMEA Biomea Fusion, Inc. compare | n/m |
| PLRX Pliant Therapeutics, Inc. | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| GANX Gain Therapeutics, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)